Michael Tomsicek has served on Acrivon's Board since October 2022 and chairs its Audit Committee. He has served on the board of Milestone Pharmaceuticals USA since April 2019. He was Chief Financial Officer of CRISPR Therapeutics AG from November 2017 to October 2021 and Chief Financial Officer of Abiomed from July 2015 to August 2017. Mr. Tomsicek holds an M.B.A. and a B.S. in engineering, both from the University of Wisconsin.